Piperlongumine suppresses proliferation of human oral squamous cell carcinoma through cell cycle arrest, apoptosis and senescence

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Chen, San Yuan ^a,b   Liu, Geng Hung ^b   Chao, Wen Ying ^c   Shi, Chung Sheng ^d   Lin, Ching Yen ^a   Lim, Yun Ping ^e   Lu, Chieh Hsiang ^a   Lai, Peng Yeh ^b   Chen, Hau Ren ^b   Lee, Ying Ray ^a,c  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^c MIN HWEI COLLEGE OF HEALTH CARE MANAGEMENT   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cell cycle arrest; Human oral squamous cell carcinoma; Piperlongumine; Senescence

Indexed keywords

CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PIPERLONGUMINE; PLANT MEDICINAL PRODUCT; PROTEIN P21; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PIPERLONGUMININE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BETEL NUT; CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; MALE; MICROSCOPY; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; SENESCENCE; WESTERN BLOTTING; CELL AGING; CELL CYCLE CHECKPOINT; DRUG EFFECTS; METABOLISM; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIOXOLANES; DNA FRAGMENTATION; HUMANS; MOUTH NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84964545017     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040616     Document Type: Article

References (37)

1. Ng, S.H.; Yen, T.C.; Liao, C.T.; Chang, J.T.; Chan, S.C.; Ko, S.F.; Wang, H.M.; Wong, H.F. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: A prospective study of 124 patients with histologic correlation. J. Nucl. Med. 2005, 46, 1136-1143. [PubMed]
2. Chung, T.T.; Pan, M.S.; Kuo, C.L.; Wong, R.H.; Lin, C.W.; Chen, M.K.; Yang, S.F. Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 2011, 32, 1063-1068.[CrossRef] [PubMed]
3. Chen, Y.K.; Huang, H.C.; Lin, L.M.; Lin, C.C. Primary oral squamous cell carcinoma: An analysis of 703 cases in southern Taiwan. Oral Oncol. 1999, 35, 173-179. [CrossRef]
4. Sargeran, K.; Murtomaa, H.; Safavi, S.M.; Vehkalahti, M.M.; Teronen, O. Survival after diagnosis of cancer of the oral cavity. Br. J. Oral Maxillofac. Surg. 2008, 46, 187-191.[CrossRef] [PubMed]
5. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90. [CrossRef] [PubMed]
6. Chen, J.Y.; Hung, C.C.; Huang, K.L.; Chen, Y.T.; Liu, S.Y.; Chiang, W.F.; Chen, H.R.; Yen, C.Y.; Wu, Y.J.; Ko, J.Y. et al. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia 2008, 10, 1393-1401.[CrossRef] [PubMed]
7. Chiu, C.C.; Chen, B.H.; Hour, T.C.; Chiang, W.F.; Wu, Y.J.; Chen, C.Y.; Chen, H.R.; Chan, P.T.; Liu, S.Y.; Chen, J.Y. Betel quid extract promotes oral cancer cell migration by activating a muscarinic M4 receptor-mediated signaling cascade involving SFKs and ERK1/2. Biochem. Biophys. Res. Commun. 2010, 399, 60-65.[CrossRef] [PubMed]
8. Lee, H.C.; Yin, P.H.; Yu, T.N.; Chang, Y.D.; Hsu, W.C.; Kao, S.Y.; Chi, C.W.; Liu, T.Y.; Wei, Y.H. Accumulation of mitochondrial DNA deletions in human oral tissues—Effects of betel quid chewing and oral cancer. Mutat. Res. 2001, 493, 67-74. [CrossRef]
9. Chen, P.H.; Shieh, T.Y.; Ho, P.S.; Tsai, C.C.; Yang, Y.H.; Lin, Y.C.; Ko, M.S.; Tsai, P.C.; Chiang, S.L.; Tu, H.P.; et al. Prognostic factors associated with the survival of oral and pharyngeal carcinoma in Taiwan. BMC Cancer 2007, 7, 101. [CrossRef] [PubMed]
10. Raj, L.; Ide, T.; Gurkar, A.U.; Foley, M.; Schenone, M.; Li, X.; Tolliday, N.J.; Golub, T.R.; Carr, S.A.; Shamji, A.F.; Stern, A.M.; et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475, 231-234. [CrossRef] [PubMed]
11. Roh, J.L.; Kim, E.H.; Park, J.Y.; Kim, J.W.; Kwon, M.; Lee, B.H. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget 2014, 5, 9227-9238. [CrossRef] [PubMed]
12. Gong, L.H.; Chen, X.X.; Wang, H.; Jiang, Q.W.; Pan, S.S.; Qiu, J.G.; Mei, X.L.; Xue, Y.Q.; Qin, W.M.; Zheng, F.Y. et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid. Med. Cell. Longev. 2014, 2014, 906804. [CrossRef] [PubMed]
13. Fruehauf, J.P.; Meyskens, F.L., Jr. Reactive oxygen species: A breath of life or death? Clin. Cancer Res. 2007, 13, 789-794. [CrossRef] [PubMed]
14. Wondrak, G.T. Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. Antioxid. Redox Signal. 2009, 11, 3013-3069. [CrossRef] [PubMed]
15. Lee, A.C.; Fenster, B.E.; Ito, H.; Takeda, K.; Bae, N.S.; Hirai, T.; Yu, Z.X.; Ferrans, V.J.; Howard, B.H.; Finkel, T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 1999, 274, 7936-7940. [CrossRef] [PubMed]
16. Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009, 136, 823-837. [CrossRef] [PubMed]
17. Bahar, G.; Feinmesser, R.; Shpitzer, T.; Popovtzer, A.; Nagler, R.M. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007, 109, 54-59. [CrossRef] [PubMed]
18. Korde, S.D.; Basak, A.; Chaudhary, M.; Goyal, M.; Vagga, A. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. Oncology 2011, 80, 382-389. [CrossRef] [PubMed]
19. Lee, Y.R.; Wu, W.C.; Ji, W.T.; Chen, J.Y.; Cheng, Y.P.; Chiang, M.K.; Chen, H.R. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J. Biomed. Sci. 2012, 19, 9. [CrossRef] [PubMed]
20. Sherr, C.J.; Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9, 1149-1163. [CrossRef] [PubMed]
21. Boulaire, J.; Fotedar, A.; Fotedar, R. The functions of the CDK-cyclin kinase inhibitor p21WAF1. Pathol. Biol. 2000, 48, 190-202. [PubMed]
22. Chen, Y.; Liu, J.M.; Xiong, X.X.; Qiu, X.Y.; Pan, F.; Liu, D.; Lan, S.J.; Jin, S.; Yu, S.B.; Chen, X.Q. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP. Oncotarget 2015, 6, 6406-6421. [CrossRef] [PubMed]
23. Wang, F.; Mao, Y.; You, Q.; Hua, D.; Cai, D. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway. Int. J. Immunopathol. Pharmacol. 2015, 28, 362-373. [CrossRef] [PubMed]
24. Han, S.S.; Son, D.J.; Yun, H.; Kamberos, N.L.; Janz, S. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leukemia Res. 2013, 37, 146-154. [CrossRef] [PubMed]
25. Shrivastava, S.; Kulkarni, P.; Thummuri, D.; Jeengar, M.K.; Naidu, V.G.; Alvala, M.; Redddy, G.B.; Ramakrishna, S. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Apoptosis 2014, 19, 1148-1164. [CrossRef] [PubMed]
26. Kahlem, P.; Dorken, B.; Schmitt, C.A. Cellular senescence in cancer treatment: Friend or foe? J. Clin. Investig. 2004, 113, 169-174. [CrossRef] [PubMed]
27. ink4a in oral squamous cell carcinoma lines by 5-AZA-21-deoxycytidine treatment induces a senescence-like state. Oncogene 1998, 17, 3445-3453. [CrossRef] [PubMed]
28. Yao, J.X.; Yao, Z.F.; Li, Z.F.; Liu, Y.B. Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. Asian Pac. J. Cancer Prev. 2014, 15, 3211-3217. [CrossRef] [PubMed]
29. Ginzburg, S.; Golovine, K.V.; Makhov, P.B.; Uzzo, R.G.; Kutikov, A.; Kolenko, V.M. Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2014, 74, 177-186. [CrossRef] [PubMed]
30. Makhov, P.; Golovine, K.; Teper, E.; Kutikov, A.; Mehrazin, R.; Corcoran, A.; Tulin, A.; Uzzo, R.G.; Kolenko, V.M. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br. J. Cancer 2014, 110, 899-907. [CrossRef] [PubMed]
31. Wang, Y.; Wang, J.W.; Xiao, X.; Shan, Y.; Xue, B.; Jiang, G.; He, Q.; Chen, J.; Xu, H.G.; Zhao, R.X.; et al. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis. 2013, 4, e824. [CrossRef] [PubMed]
32. Laurent, A.; Nicco, C.; Chereau, C.; Goulvestre, C.; Alexandre, J.; Alves, A.; Levy, E.; Goldwasser, F.; Panis, Y.; Soubrane, O. et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005, 65, 948-956. [PubMed]
33. Trachootham, D.; Lu, W.; Ogasawara, M.A.; Nilsa, R.D.; Huang, P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10, 1343-1374. [CrossRef] [PubMed]
34. Cabello, C.M.; Bair, W.B., 3rd; Wondrak, G.T. Experimental therapeutics: Targeting the redox Achilles heel of cancer. Curr. Opin. Investig. Drugs 2007, 8, 1022-1037. [PubMed]
35. Liu, J.M.; Pan, F.; Li, L.; Liu, Q.R.; Chen, Y.; Xiong, X.X.; Cheng, K.; Yu, S.B.; Shi, Z.; Yu, A.C.; et al. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem. Biophys. Res. Commun. 2013, 437, 87-93. [CrossRef] [PubMed]
36. Saeidnia, S.; Abdollahi, M. Antioxidants: Friends or foe in prevention or treatment of cancer: The debate of the century. Toxicol. Appl. Pharmacol. 2013, 271, 49-63. [CrossRef] [PubMed]
37. Liu, Q.R.; Liu, J.M.; Chen, Y.; Xie, X.Q.; Xiong, X.X.; Qiu, X.Y.; Pan, F.; Liu, D.; Yu, S.B.; Chen, X.Q. Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways. Oxid. Med. Cell. Longev. 2014, 2014, 653732. [CrossRef] [PubMed].